Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Author:

Wieduwilt Matthew J.1,Metheny Leland2,Zhang Mei-Jie34,Wang Hai-Lin3,Estrada-Merly Noel3,Marks David I.5,Al-Homsi A. Samer6,Muffly Lori7ORCID,Chao Nelson8ORCID,Rizzieri David9ORCID,Gale Robert Peter10,Gadalla Shahinaz M.11ORCID,Cairo Mitchell12,Mussetti Alberto1314,Gore Steven15,Bhatt Vijaya Raj16ORCID,Patel Sagar S.17ORCID,Michelis Fotios V.18ORCID,Inamoto Yoshihiro19,Badawy Sherif M.2021,Copelan Edward22,Palmisiano Neil23,Kharfan-Dabaja Mohamed A.24ORCID,Lazarus Hillard M.25,Ganguly Siddhartha26,Bredeson Christopher27,Diaz Perez Miguel Angel28,Cassaday Ryan29,Savani Bipin N.30ORCID,Ballen Karen31,Martino Rodrigo32ORCID,Wirk Baldeep33,Bacher Ulrike34ORCID,Aljurf Mahmoud35,Bashey Asad36,Murthy Hemant S.24,Yared Jean A.37,Aldoss Ibrahim38,Farhadfar Nosha39,Liu Hongtao40ORCID,Abdel-Azim Hisham41,Waller Edmund K.42ORCID,Solh Melhem43,Seftel Matthew D.44,van der Poel Marjolein45,Grunwald Michael R.22,Liesveld Jane L.46,Kamble Rammurti T.47,McGuirk Joseph26ORCID,Munker Reinhold48,Cahn Jean-Yves49,Lee Jong Wook50,Freytes César O.51,Krem Maxwell M.48ORCID,Winestone Lena E.52ORCID,Gergis Usama53,Nathan Sunita54,Olsson Richard F.5556ORCID,Verdonck Leo F.57,Sharma Akshay58ORCID,Ringdén Olle59ORCID,Friend Brian D.60ORCID,Cerny Jan61ORCID,Choe Hannah62,Chhabra Saurabh363ORCID,Nishihori Taiga64ORCID,Seo Sachiko65ORCID,George Biju66ORCID,Baxter-Lowe Lee Ann67ORCID,Hildebrandt Gerhard C.48ORCID,de Lima Marcos68ORCID,Litzow Mark69ORCID,Kebriaei Partow70,Hourigan Christopher S.71ORCID,Abid Muhammad Bilal72,Weisdorf Daniel J.73ORCID,Saber Wael3

Affiliation:

1. University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK;

2. University Hospitals Seidman Cancer Center, Cleveland, OH;

3. Center for International Blood and Marrow Transplant Research, Department of Medicine, and

4. Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI;

5. Adult Bone Marrow Transplant, University Hospitals Bristol National Health Service Trust, Bristol, UK;

6. New York University Langone Health, New York, NY;

7. Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA;

8. Division of Cell Therapy and Hematology, Department of Medicine, Duke University Medical Center, Durham, NC;

9. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC;

10. Haematology Research Centre, Department of Immunology and Inflammation, Imperial College London, London, UK;

11. Division of Cancer Epidemiology and Genetics, Clinical Genetics Branch, National Cancer Institute, National Institutes of Health, Rockville, MD;

12. Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, Valhalla, NY;

13. Hematology Department, Institut Catalá d’Oncologia-Hospitalet, Barcelona, Spain;

14. Institut d’Investigació Biomédica de Bellvitge-Institut Català d’Oncologia, l’Hospitalet de Llobregat, El Prat de Llobregat, Spain;

15. Yale New Haven Hospital, New Haven, CT;

16. The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE;

17. Blood and Marrow Transplant Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT;

18. Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada;

19. Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan;

20. Division of Hematology, Oncology and Stem Cell Transplant, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL;

21. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL;

22. Deparment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC;

23. Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA;

24. Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL;

25. University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH;

26. Division of Hematological Malignancies and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS;

27. The Ottawa Hospital Transplant and Cellular Therapy Program, Ottawa, ON, Canada;

28. Department of Hematology/Oncology, Hospital Infantil Universitario Niño Jesus, Madrid, Spain;

29. Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA;

30. Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN;

31. Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA;

32. Division of Clinical Hematology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain;

33. Bone Marrow Transplant Program, Penn State Cancer Institute, Hershey, PA;

34. Department of Hematology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland;

35. Department of Oncology, King Faisal Specialist Hospital Center and Research, Riyadh, Saudi Arabia;

36. Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA;

37. Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD;

38. City of Hope Medical Center, Duarte, CA;

39. Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, FL;

40. Section of Hematology/Oncology, University of Chicago Medicine, Chicago, IL;

41. Division of Hematology, Oncology and Blood & Marrow Transplantation, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA;

42. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA;

43. The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA;

44. Department of Medicine, University of British Columbia, Vancouver, BC, Canada;

45. Maastricht University Medical Center, Maastricht, The Netherlands;

46. Department of Medicine, University of Rochester Medical Center, Rochester, NY;

47. Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX;

48. Markey Cancer Center, University of Kentucky, Lexington, KY;

49. Department of Hematology, Centre Hospitalier Universitaire Grenoble Alpes, Université Grenoble Alpes, Grenoble, France;

50. Division of Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea;

51. University of Texas Health Science Center at San Antonio, San Antonio, TX;

52. Division of Allergy, Immunology, and Blood and Marrow Transplant, University of California San Francisco Benioff Children’s Hospitals, San Francisco, CA;

53. Department of Medical Oncology, Division of Hematological Malignancies, Thomas Jefferson University, Philadelphia, PA;

54. Section of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, Chicago, IL;

55. Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;

56. Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden;

57. Department of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands;

58. Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis, TN;

59. Translational Cell Therapy Group, Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden;

60. Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX;

61. Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, MA;

62. The Ohio State University Wexner Medical Center, James Comprehensive Cancer Center, Columbus, OH;

63. Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI;

64. Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL;

65. Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan;

66. Christian Medical College, Vellore, India;

67. Children’s Hospital Los Angeles, Los Angeles, CA;

68. Department of Medicine, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH;

69. Division of Hematology and Transplant Center, Mayo Clinic Rochester, Rochester, MN;

70. Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX;

71. Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;

72. Divisions of Hematology/Oncology and Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; and

73. Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN

Abstract

Abstract The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.

Publisher

American Society of Hematology

Subject

Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3